Neuronetics has received 510(k) clearance from the US Food and Drug Administration (FDA) for its D-Tect MT Accessory.

The technology simplifies motor threshold (MT) determination for physicians by visually reporting the magnitude of finger movements during MT mapping for the treatment of major depressive disorder (MDD).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Additionally, it enables the determination of MT to be performed by a single person.

Designed to be used as an accessory to the NeuroStar System, the new MT detection device recognises movement in three hand areas without requiring cords or sensors to be attached to the patient.

The D-Tect MT Accessory complements NeuroStar’s Fast MT and MT Cap offerings and provides more data to clinicians, including a comparison of the response to the existing pulse against the response to the previous pulse.

Neuronetics expects the new technology to save up to 40% of the average time spent on MT determination by clinicians.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Neuronetics R&D and Clinical vice-president Cory Anderson said: “The FDA clearance for the D-Tect MT Accessory is the next chapter in our plan to simplify and accelerate the MT determination for NeuroStar providers.

“This product aids physicians as they determine the treatment location and treatment level for new patients, and we’re excited to announce that this patent-pending technology is compatible with all new and existing NeuroStar systems.”

Initially, the company will make D-Tect available through a limited commercial launch. This would be followed by a national rollout commencing in mid-September.

Practices will get training on the D-Tect MT Accessory at NeuroStar University, which was recently opened in Charlotte, North Carolina, US.

Neuronetics’ MT Cap technology received 510(k) clearance from the FDA last December.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact